Literature DB >> 9346269

Sulphasalazine therapy in chronic uveitis of children with chronic arthritis.

J L Huang1, I J Hung, K H Hsieh.   

Abstract

Four children with chronic arthritis (3 juvenile rheumatoid arthritis and 1 juvenile ankylosing spondylitis) and poorly controlled chronic uveitis, were given sulphasalazine (SASP) therapy for a mean period of 3.3 years. Three patients showed an excellent response, as evidenced by a reduction of inflammatory cells in the anterior chamber of the eyes and improvement of visual acuity. The response occurred after a mean of 7.7 weeks. These data suggested SASP therapy may have a role in the treatment of chronic anterior uveitis in children with chronic arthritis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9346269

Source DB:  PubMed          Journal:  Asian Pac J Allergy Immunol        ISSN: 0125-877X            Impact factor:   2.310


  2 in total

Review 1.  Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis.

Authors:  A Heiligenhaus; H Michels; C Schumacher; I Kopp; U Neudorf; T Niehues; H Baus; M Becker; B Bertram; G Dannecker; C Deuter; I Foeldvari; M Frosch; G Ganser; M Gaubitz; G Gerdes; G Horneff; A Illhardt; F Mackensen; K Minden; U Pleyer; M Schneider; N Wagner; M Zierhut
Journal:  Rheumatol Int       Date:  2011-11-15       Impact factor: 2.631

2.  Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative.

Authors:  Tamas Constantin; Ivan Foeldvari; Jordi Anton; Joke de Boer; Severine Czitrom-Guillaume; Clive Edelsten; Raz Gepstein; Arnd Heiligenhaus; Clarissa A Pilkington; Gabriele Simonini; Yosef Uziel; Sebastian J Vastert; Nico M Wulffraat; Anne-Mieke Haasnoot; Karoline Walscheid; Annamária Pálinkás; Reshma Pattani; Zoltán Györgyi; Richárd Kozma; Victor Boom; Andrea Ponyi; Angelo Ravelli; Athimalaipet V Ramanan
Journal:  Ann Rheum Dis       Date:  2018-03-28       Impact factor: 19.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.